Hypoglycemia in Children Taking Propranolol for the Treatment of Infantile Hemangioma

Kristen E. Holland, MD; Ilona J. Frieden, MD; Peter C. Frommelt, MD; Anthony J. Mancini, MD; David Wyatt, MD; Beth A. Drolet, MD

Background: Propranolol hydrochloride has been prescribed for decades in the pediatric population for a variety of disorders, but its effectiveness in the treatment of infantile hemangiomas (IHs) was only recently discovered. Since then, the use of propranolol for IHs has exploded because it is viewed as a safer alternative to traditional therapy.

Observations: We report the cases of 3 patients who developed symptomatic hypoglycemia during treatment with propranolol for their IHs and review the literature to identify other reports of propranolol-associated hypoglycemia in children to highlight this rare adverse effect.

Conclusions: Although propranolol has a long history of safe and effective use in infants and children, understanding and recognition of deleterious adverse effects is critical for physicians and caregivers. This is especially important when new medical indications evolve as physicians who may not be as familiar with propranolol and its adverse effects begin to recommend it as therapy.

Arch Dermatol. 2010;146(7):775-778
CASE 2

A healthy 18-month-old girl with a nasal tip IH, previously treated with topical clobetasol propionate (at age 2-9 months) was started on propranolol for continued growth of her hemangioma. There was no history of hypoglycemia or other medications. The initial dose of propranolol hydrochloride, 0.5 mg/kg/d, divided and given twice daily, was titrated to 1 mg/kg/d over several weeks. After 2 months there was minimal change in the size of the IH, and the propranolol hydrochloride dosage was increased to 1.25 mg/kg/d, divided and given twice daily. During an intercurrent illness (fever, nausea, vomiting), propranolol was withheld. After 4 days she began eating normally, and propranolol was restarted. The day prior to hospitalization, she ate dinner at 5 PM, had propranolol at 6 PM, and went to bed. The mother found her 13 hours later in bed, cold, clammy, and unresponsive. A 10-minute seizure occurred prior to transport by ambulance to the ED. Her rectal temperature was 33.4°C, her pulse was 84 bpm, and her BP was 98/62 mm Hg. Thirty minutes after arrival, she had another seizure and was given lorazepam. Her blood glucose level was 19 mg/dL, her serum glucose level was 24 mg/dL, and her urine ketones level was 15 mg/dL. She was given 9 mL of a 25% dextrose solution intravenously, which resulted in normalization of her glucose level. She was admitted to the hospital and had no further episodes of hypoglycemia or seizures for the next 48 hours (fingerstick glucose level checked every 2-4 hours). Her organic and amino acid levels were normal.

CASE 3

A healthy 5-week-old, full-term girl presented with a nasal tip IH that was increasing in size rapidly. She was started on oral propranolol hydrochloride suspension (20 mg/5 mL) at 1 mg/kg/d and gradually titrated up to 2 mg/kg/d, divided and given 3 times daily over 4 months. She was taking no other medications and had no history of hypoglycemia. She remained on a dosage of 2 mg/kg/d for 8.5 months without adverse effects and with marked improvement in the appearance of her IH. At 10 months of age, 2.5 hours after having a normal breakfast and receiving her morning propranolol dose, she was found by her mother to be limp, pale, and breathing deeper and faster than usual. Emergency medical services were activated, and the paramedics found her to have a serum glucose level of 20 mg/dL. She was given dextrose intravenously and taken to the ED, where her rectal temperature was 38.7°C. Her parents noted that she had developed a cough and runny nose 1 day prior, but that they felt she had been eating normally. A nasopharyngeal swab for respiratory syncytial virus was taken, and the findings were positive. Findings from chest radiography were normal, and her pulse oximetry level remained above 97% on room air. She was admitted to the pediatric unit, and her propranolol hydrochloride dosing was decreased to twice daily (1.3 mg/kg/d). Albuterol nebulizer treatments and IV fluids were administered. Her blood glucose levels were stable overnight (118, 119, and 82 mg/dL), her oral intake was appropriate for her age, and she was discharged home after 1 day of hospitalization. The parents were instructed to give the propranolol only twice daily until follow-up with the dermatology and cardiology departments was arranged. She has since resumed the 3 times daily dosing of propranolol hydrochloride at 2 mg/kg/d without further difficulty.

COMMENT

Treatment of IHs is designed to control growth, minimize deformity, preserve function, and minimize psychological and emotional stress. Systemic pharmacotherapy is most often used to treat large IHs that present a surgical challenge or those causing functional or life-threatening problems. Well-designed studies evaluating the efficacy and safety of various treatments are lacking, with anecdotal reports and case series leading to currently accepted treatments. Agents traditionally used in treating IHs include oral and intralesional corticosteroids, but other treatments, such as interferon alfa and vinca alkaloids, have also been used. Propranolol has recently been used in the treatment of IHs after improvement in color, softening, growth arrest, and even regression of an IH was incidentally noted when propranolol was started for treatment of hypertrophic myocardiopathy. Since then, the use of propranolol for IHs has soared because it is viewed as having a lower adverse-effect profile than other systemic therapies used for treating IHs.

Propranolol has been used in children for many years both for cardiac and noncardiac diseases. Although it has been well studied in adults, experience in infants and children has been mainly anecdotal. The most common serious adverse effects of propranolol include bradycardia and hypotension. Bronchospasm can be seen in patients with reactive airway disease. Other adverse effects include congestive heart failure, depression, nausea, vomiting, abdominal cramping, sleep disturbance, and night terrors. The association between propranolol and hypoglycemia in infants and children is well known and is noted in the product insert. However, this adverse effect is best recognized during the neonatal period with older infants and children considered to be low risk. Because treatment of IHs is typically started outside of the neonatal period, when maintenance of euglycemia is more robust, the risk of hypoglycemia may be overlooked by prescribing physicians. To better define this risk, a literature review of hypoglycemia associated with propranolol therapy in infants and children outside of the neonatal period was performed. Twenty-one cases were identified (Table 1). Eleven (52%) were receiving long-term treatment (≥5 days) at doses ranging from 2 to 14 mg/kg/d. The remaining patients received propranolol adjutively for growth hormone testing (6 patients), intraoperatively (2 patients), and through accidental overdose (2 patients). Seventeen of the 18 identified cases in which the oral intake status was known (94%) occurred after an overnight to 24-hour fast, occasionally in the setting of poor oral intake the preceding day(s). In all but 1 of the patients receiving long-term propranolol therapy, symptoms of hypoglycemia generally occurred in the morning, with a number of the children being unresponsive or unarousable when parents went to check on them in the morn-


ing. One patient receiving long-term propranolol therapy had an episode similar to those of 2 of our patients, with development of hypoglycemia, despite normal oral intake, 1 to 2 hours after propranolol was given.11 Aside from 4 patients who proved to have a growth hormone deficiency, the patients had no known concomitant medical conditions and were not taking medications that could be implicated as the cause of the hypoglycemia. One patient experienced severe cerebral damage and epilepsy,12 but the remainder recovered without long-term complications.

Although most of the reported patients who developed hypoglycemia were prescribed higher doses of propranolol, 2 of the 3 patients described herein were taking relatively small doses, suggesting that hypoglycemia associated with propranolol may not be dose dependent. While the mechanism by which hypoglycemia develops in some children taking propranolol is not completely understood, normal glucose homeostasis is thought to be impaired through inhibition of β-adrenergic mediated glycogenolysis, gluconeogenesis, and lipolysis. Children and infants seem to be at higher risk for this adverse effect because their glucose utilization rates are higher in the fasting state (as much as 3-fold higher in infants),13 attributed partly to their greater brain mass relative to their body weight.13 In addition, glycogen stores are lower in infants and children compared with adults, leading to a reduced fasting ability. This may have been an additional factor in our second case, because glycogen stores may not have been replenished from the previous low intake illness.

Clinical manifestations of hypoglycemia in infants can vary widely:

**Early, counterregulatory epinephrine effects (which may be masqueraded by β-adrenergic blockade):**

- Sweating
- Shakiness
- Tachycardia
- Anxiety
- Hunger

**Late, neuroglycopenia:**

- Lethargy
- Stupor
- Poor feeding
- Seizures
- Apnea
- Loss of consciousness
- Hypotermia

Mild hypoglycemia produces symptoms associated with counterregulatory epinephrine action, including sweating, shakiness, tachycardia, anxiety, and hunger.1,3 These may be absent or difficult to detect in infants, especially when propranolol-induced β-adrenergic blockade is present. The fussiness seen in our first patient may have reflected this early symptomatic phase. More severe hypoglycemia produces symptoms of neuroglycopenia,
including lethargy, stupor, poor feeding, seizures, apnea, loss of consciousness, and hypothermia. The patients in 2 of our 3 cases had clinically significant hypothermia. Permanent neurologic damage is rare.15

As the use of propranolol in infants with IHs increases, physicians must be aware of the potential for hypoglycemia. While recognition of signs or symptoms of hypoglycemia may prompt early intervention, measures may be taken to decrease the risk of hypoglycemia. Propranolol should be discontinued during intercurrent illness, especially in the setting of restricted oral intake. For those whose treatment cannot be interrupted, support with glucose-containing IV fluids during perioperative periods is indicated. Preoperative blood glucose levels may identify additional patients whose symptoms might otherwise be masked by preoperative medications and anesthesia.

Table 2. Considerations for Theoretical Increased Risk of Adverse Effects in Patients With Infantile Hemangiomas

<table>
<thead>
<tr>
<th>Population</th>
<th>Adverse Effect</th>
<th>Reason for Concern</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1 y of age, particularly LBW infants</td>
<td>Hypoglycemia</td>
<td>Limited glycogen stores, inability to communicate symptoms</td>
</tr>
<tr>
<td>Patients previously treated with systemic steroids</td>
<td>Hypoglycemia</td>
<td>Muted counterregulatory cortisol response, secondary to adrenal suppression</td>
</tr>
<tr>
<td>Hemangioma-related high output cardiac failure (ie, large liver hemangioma)</td>
<td>Decompensation of HF</td>
<td>Decreased heart rate/contractility limits cardiac response to high output demands</td>
</tr>
</tbody>
</table>

Abbreviations: HF, heart failure; LBW, low birth weight.

Although propranolol has a long history of safe and effective use in infants and children for the treatment of many conditions, understanding and recognition of deleterious adverse effects is critical for physicians and caregivers. This is especially important when new medical indications evolve as physicians who may not be as familiar with propranolol and its adverse effects begin to recommend it as therapy (as in the treatment of IH). Clearly outlined and safe protocols for initiation and chronic dosage should be developed in conjunction with randomized trials that document efficacy in the treatment of IH.

Accepted for Publication: March 23, 2010.
Correspondence: Kristen E. Holland, MD, Department of Dermatology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226 (kholland@mcw.edu).

Author Contributions: All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Holland, Frommelt, and Drolet. Acquisition of data: Holland, Frieden, Frommelt, Mancini, and Drolet. Drafting of the manuscript: Holland, Frommelt, and Drolet. Critical revision of the manuscript for important intellectual content: Holland, Frieden, Mancini, Wyatt, and Drolet. Administrative, technical, and material support: Holland and Drolet. Study supervision: Frieden.

Financial Disclosure: Drs Drolet and Frieden are consultants for Pierre Fabre Dermatology. Dr Wyatt is a consultant for Genentech and Novo Nordisk.

REFERENCES